Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
Ozempic and Wegovy might be making it harder for physicians to guide patients toward lifestyle changes − the real key to long ...
More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...
The rise of weight loss drugs is not only changing individual lives, but also reshaping large sections of the economy.
Doctors say early obesity intervention can help prevent later health problems. But prescribing GLP-1s, such as Ozempic and ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...
A rival drug company is celebrating results claiming its drug helps patients lose more weight than Novo Nordisk’s Wegovy. Eli ...
On Nov. 26, the Biden administration announced a plan to require Medicare and Medicaid to cover weight loss medications like ...
A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...
Millions of Americans would be eligible to have popular drugs used for weight loss like Wegovy or Ozempic covered by Medicare ...
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...